GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Ningbo Menovo Pharmaceutical Co 603538.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

21.17

-2.22%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥1.50bn

FY2016FY2025

Net income

CN¥102.2m

FY2016FY2025

Free cash flow

CN¥45.5m

FY2016FY2025

Shareholders' equity

CN¥2.34bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥1.50bnCN¥1.37bnCN¥1.22bnCN¥1.46bnCN¥1.26bnCN¥1.19bnCN¥1.18bnCN¥849.0mCN¥605.3mCN¥578.1m
Gross profitCN¥526.7mCN¥421.3mCN¥342.7mCN¥566.2mCN¥465.9mCN¥401.4mCN¥440.7mCN¥271.0mCN¥206.3mCN¥206.2m
Research and developmentCN¥109.4mCN¥99.7mCN¥95.3mCN¥98.2mCN¥88.3mCN¥73.7mCN¥53.0mCN¥39.2mCN¥32.0mCN¥31.6m
Operating incomeCN¥200.7mCN¥92.6mCN¥37.9mCN¥405.3mCN¥187.9mCN¥205.7mCN¥189.7mCN¥112.6mCN¥65.0mCN¥98.6m
Net incomeCN¥102.2mCN¥66.8mCN¥11.6mCN¥338.9mCN¥142.5mCN¥156.0mCN¥150.9mCN¥96.3mCN¥44.7mCN¥78.8m
Diluted earnings per share0.450.320.041.450.640.730.740.620.230.54

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥4.85bnCN¥4.65bnCN¥4.42bnCN¥4.42bnCN¥4.00bnCN¥3.06bnCN¥2.61bnCN¥2.27bnCN¥1.51bnCN¥955.3m
Cash and short-term investments—CN¥739.9mCN¥724.7mCN¥1.01bnCN¥793.2mCN¥368.8mCN¥442.9mCN¥369.9mCN¥258.6mCN¥125.2m
Total liabilitiesCN¥2.40bnCN¥2.36bnCN¥2.24bnCN¥2.25bnCN¥2.02bnCN¥1.30bnCN¥1.05bnCN¥930.9mCN¥351.2mCN¥224.3m
DebtCN¥678.6mCN¥1.14bnCN¥1.30bnCN¥1.20bnCN¥1.26bnCN¥757.4mCN¥596.1mCN¥535.9mCN¥155.0mCN¥67.0m
Shareholders' equityCN¥2.34bnCN¥2.19bnCN¥2.10bnCN¥2.08bnCN¥1.75bnCN¥1.55bnCN¥1.36bnCN¥1.20bnCN¥1.12bnCN¥690.1m
Shares outstanding229m208m298m234m223m213m204m155m197m145m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥157.6mCN¥97.5mCN¥9.1mCN¥277.0mCN¥220.6mCN¥251.6mCN¥179.8mCN¥46.6mCN¥80.2mCN¥117.2m
Capital spending−CN¥112.1m−CN¥179.4m−CN¥219.5m−CN¥571.6m−CN¥529.9m−CN¥311.7m−CN¥328.1m−CN¥299.6m−CN¥86.2m−CN¥108.8m
Free cash flowCN¥45.5m−CN¥81.9m−CN¥210.4m−CN¥294.7m−CN¥309.3m−CN¥60.1m−CN¥148.3m−CN¥253.0m−CN¥6.1mCN¥8.4m
Dividends paid−CN¥25.9m−CN¥22.7m−CN¥59.2m−CN¥30.3m−CN¥13.8m−CN¥16.4m−CN¥29.8m−CN¥39.1m−CN¥4.4m−CN¥2.6m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥521.2mCN¥337.7mCN¥386.3mCN¥439.5mCN¥400.8mCN¥276.5mCN¥423.8mCN¥341.2m
Gross profitCN¥159.8mCN¥91.6mCN¥158.1mCN¥149.4mCN¥132.3mCN¥86.9mCN¥118.7mCN¥124.1m
Operating incomeCN¥78.2mCN¥41.3mCN¥51.1mCN¥57.9mCN¥33.9mCN¥32.7mCN¥8.6mCN¥55.7m
Net incomeCN¥32.5mCN¥31.2mCN¥6.3mCN¥46.9mCN¥27.8mCN¥21.2mCN¥3.6mCN¥44.3m
Diluted earnings per share0.140.140.030.200.120.090.020.21
Cash from operations———CN¥38.0mCN¥18.0m−CN¥24.0m—CN¥112.0m
Capital spending−CN¥24.0m−CN¥26.0m−CN¥75.0m−CN¥4.0m−CN¥22.0m−CN¥9.0m−CN¥94.0m−CN¥11.0m
Free cash flow———CN¥34.0m−CN¥4.0m−CN¥33.0m—CN¥101.0m
Total assetsCN¥4.73bnCN¥4.60bnCN¥4.85bnCN¥4.75bnCN¥4.67bnCN¥4.64bnCN¥4.65bnCN¥4.62bn
Cash and short-term investments———CN¥697.6mCN¥645.4mCN¥679.9mCN¥739.9mCN¥785.9m
DebtCN¥39.5mCN¥544.1mCN¥678.6mCN¥966.8mCN¥1.06bnCN¥1.24bnCN¥1.13bnCN¥1.27bn
Shareholders' equityCN¥2.93bnCN¥2.38bnCN¥2.34bnCN¥2.31bnCN¥2.25bnCN¥2.22bnCN¥2.19bnCN¥2.17bn

Financial ratios

Data as of 14 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin35.0%30.7%28.2%38.9%37.0%33.6%
Operating margin11.4%9.9%3.1%28.3%16.5%19.4%
Net margin6.8%4.9%1.0%23.3%11.3%13.1%
Return on equity4.4%3.0%0.6%16.3%8.1%10.1%
Return on assets2.1%1.4%0.3%7.7%3.6%5.1%
Free cash flow yield4.9%5.5%3.2%15.0%13.9%11.0%
Revenue growth9.5%12.9%-16.5%15.8%5.4%1.1%
Earnings growth53.0%476.6%-96.6%137.7%-8.6%3.4%
Current ratio1.44x1.24x1.28x1.39x1.48x1.02x
Debt to equity0.29x0.52x0.61x0.57x0.66x0.53x
Equity ratio48.1%47.1%47.4%47.2%43.8%50.7%
Interest coverage4.10x2.77x1.27x14.69x7.52x8.82x
R&D as a share of sales7.3%7.3%7.8%6.7%7.0%6.2%
Buybacks as a share of market value-10.2%30.2%-27.2%-4.9%-4.9%-4.2%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue1.0%4.7%9.7%
Operating income-20.9%-0.5%8.2%
Net income-32.9%-8.1%2.9%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin33.0%33.5%34.0%34.2%
Operating margin10.2%13.3%14.1%14.3%
Net margin5.9%9.4%10.2%10.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings30.828.2350.812.728.425.917.116.249.6
Price to sales2.11.43.33.03.23.42.21.83.7

Dividends and splits

Per share, in the currency the company pays

Paid for 4 years. Last went ex-dividend on 9 Jul 2026.

FY2026FY2025FY2024FY2023FY2022FY2020FY2019FY2018
Paid in the year0.1550.0360.0140.1180.1420.0560.1020.077
  • 1.397-for-1 split · 8 Jun 2022
  • 6-for-5 split · 9 Jul 2018

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.